Another day another preprint on ChemRxiv! “Leveraging Atropisomerism to Obtain a Mutant-Selective c-KIT Inhibitor in Gastrointestinal Stromal Tumors” A story of privileged heterocycles, atropisomerism and kinase selectivity. chemrxiv.org/doi/full/10....
Leveraging Atropisomerism to Obtain a Mutant-Selective c-KIT Inhibitor in Gastrointestinal Stromal Tumors | ChemRxiv
Atropisomerism is a stereochemical phenomenon that is becoming increasingly prevalent in the modern drug discovery endeavor. A significant portion of small molecule drugs, including the FDA-approved multi-kinase inhibitor ripretinib, exist as unstable ...
chemrxiv.org